Log In
Print this Print this

Lipacreon, pancrelipase (Creon) (SA-001)

  Manage Alerts
Collapse Summary General Information
Company Abbott Laboratories
DescriptionPancrelipase delayed-release capsules
Molecular Target
Mechanism of ActionEnzyme replacement therapy
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentMarketed
Standard IndicationPancreatic insufficiency
Indication DetailsTreat pancreatic exocrine insufficiency (PEI); Treat pancreatic exocrine insufficiency due to chronic pancreatitis or pancreatic surgery; Treat pancreatic exocrine insufficiency due to cystic fibrosis (CF)
Regulatory Designation
PartnerAbbVie Inc.;
Eisai Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today